Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB

  • STATUS
    Recruiting
  • End date
    Apr 29, 2024
  • participants needed
    280
  • sponsor
    Azienda Unità Sanitaria Locale Reggio Emilia
Updated on 23 September 2021

Summary

This study is a prospective, randomized phase III, to evaluate if in patients with mCRC RAS/BRAF wild type on tumor tissue and RAS mutations on liquid biopsy, treating in first line with antibody anti-VEGF (bevacizumab) plus chemotherapy (FOLFIRI) is superior in terms of PFS compared to standard treatment with antibody anti-EGFR (cetuximab) plus FOLFIRI, and then in patients RAS/BRAF wild type on tumor tissue who develop RAS mutations on liquid biopsy after the beginning of the first line treatment with cetuximab plus FOLFIRI, in the absence of a clinical or radiological progression disease, to anticipate a change of treatment with bevacizumab plus FOLFIRI further impacts on the PFS.

Description

In this prospective, randomized phase III study, first of all we aim to evaluate if in patients with mCRC RAS/BRAF wild type on tumor tissue and RAS mutations on liquid biopsy, treating in first line with antibody anti-VEGF (bevacizumab) plus chemotherapy (FOLFIRI) is superior in terms of PFS compared to standard treatment with antibody anti-EGFR (cetuximab) plus FOLFIRI, and then in patients RAS/BRAF wild type on tumor tissue who develop RAS mutations on liquid biopsy after the beginning of the first line treatment with cetuximab plus FOLFIRI, in the absence of a clinical or radiological progression disease, to anticipate a change of treatment with bevacizumab plus FOLFIRI further impacts on the PFS.

Patients RAS mut at first liquid biopsy will be randomized with a 1:1 ratio, to receive FOLFIRI plus cetuximab or FOLFIRI plus bevacizumab.

Patients with RAS wt at first biopsy will be treated with FOLFIRI plus cetuximab up to 8 cycles outside the protocol. Patients not progressed after 4 months (8 cycles of treatment) will undergo to a second liquid biopsy. In case of mutation of RAS, the patients will be randomized with a 1:1 ratio to continue cetuximab or to switch to bevacizumab.

The treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, other conditions compromise subject safety or patient refusal.

Plasma samples will be analyzed for mutations of KRAS, NRAS and in BRAF V600 using the Idylla system (Biocartis). Samples will be retrospectively analysed by next generation sequencing using the Oncomine Pan-Cancer Cell-free Assay, which assesses genetic alterations in 52 driver genes, in order to evaluate the possible correlation of tumor heterogeneity with patients' outcome.

With this study we could identify the best monoclonal antibody treatment in mCRC RAS/BRAF wild type on tumor tissue and RAS mutated on liquid biopsy and if liquid biopsy can be used in clinical practice as an integrated analysis to mutational tissue evaluation, to identify RAS mutations not detected on tissue.

Details
Condition Rectal disorder, tumors, colorectal, Colorectal Cancer, Colon Cancer Screening, colorectal neoplasm, RAS Mutation, cancer, colorectal, Rectal Disorders, colorectal tumor, Colon cancer; rectal cancer, Metastatic Colorectal Cancer, colorectal cancers
Treatment Cetuximab, bevacizumab, Irinotecan, 5-FU, Calcium levofolinate
Clinical Study IdentifierNCT04776655
SponsorAzienda Unità Sanitaria Locale Reggio Emilia
Last Modified on23 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Provision of written informed consent
Male or female > 18 years of age
Histologically confirmed diagnosis of colorectal adenocarcinoma RAS/BRAF wild type (analysed either on primary and/or related metastasis)
Initially unresectable metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease
Patient with left colorectal cancer
Patients suitable for first line chemotherapy
Life expectancy > 3 months
At least one site of measurable disease per RECIST criteria ver. 1.1
ECOG Performance status = 2
Adequate bone marrow, liver and renal function assessed before starting study treatment
If DPD status is known it must be wild type. No restrictions are applied if DPD status in unknown
Women of childbearing potential must have a negative blood pregnancy test within 24 hr prior to the start of study treatment. For this trial, women of childbearing potential are defined as all women after puberty, unless they are postmenopausal for at least 12 months, are surgically sterile, or are sexually inactive
Subjects and their partners must be willing to avoid pregnancy during the trial and until 5 months for WOCBP (Women of Childbearing Potential) and 7 months for male subjects with female partners of WOCBP after the last trial treatment. Male subjects with female partners of childbearing potential and female subjects of childbearing potential must, therefore, be willing to use adequate contraception as approved by the investigator (barriers contraceptive measure or oral contraception)

Exclusion Criteria

Previous chemotherapy treatment, with the exception of patient treated in adjuvant setting completed at least 6 months before the randomization
Any contraindication to the use of Cetuximab, Bevacizumab, Irinotecan, 5FU or folinic acid
Radiotherapy to any site within 4 weeks before the randomization
Serious, non-healing wound, ulcer, or bone fracture
Evidence of bleeding diathesis or coagulopathy
Uncontrolled hypertension and prior history of hypertensive crisis or hypertensive encephalopathy
Additional malignancy in the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy
Active and untreated brain (CNS) metastases and/or carcinomatous meningitis
Active infection requiring systemic therapy or active disseminated intravascular coagulation
History of Human Immunodeficiency Virus (HIV) (HIV 1/2 antobodies)
Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection
Chronic, daily treatment with high-dose aspirin (>325 mg/day)
Any previous venous thromboembolism > NCI CTCAE Grade 3
History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to the first study treatment. History of acute or subacute intestinal occlusion or chronic inflammatory bowel disease or chronic diarrhoea
Current, recent (within 10 days prior to study treatment start) or ongoing treatment with anticoagulants for therapeutic purposes
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study
History of any severe hypersensitivity reactions to any monoclonal antibody
A significant concomitant disease which, in the investigating physician's opinion, rules out the patient's participation in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note